📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Development of Potent Pf CLK3 Inhibitors Based on TCMDC-135051 as a New Class of Antimalarials (2020)

First Author: Mahindra A

Attributed to: Development of next generation anti-malarials targeting the essential parasite protein kinase PfCLK3 funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1021/acs.jmedchem.0c00451

PubMed Identifier: 32787140

Publication URI: http://europepmc.org/abstract/MED/32787140

Type: Journal Article/Review

Parent Publication: Journal of Medicinal Chemistry

Issue: 17

ISSN: 0022-2623